2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies

BACKGROUND: Patients with hematologic malignancies remain at higher risk for developing severe SARS-CoV-2 infections and have reduced immune responses to vaccines. METHODS: A prospective observational study was conducted at Brigham and Women’s Hospital and Dana-Farber Cancer Institute from January 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Aleissa, Muneerah M, Davey, Sonya, Rooks, Rebecca, Izaguirre, Natalie E, Yates, Bridget, Kanwal, Urwah, Baden, Lindsey R, Issa, Nicolas C, Sherman, Amy C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677953/
http://dx.doi.org/10.1093/ofid/ofad500.1956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677953/
http://dx.doi.org/10.1093/ofid/ofad500.1956

Ejemplares similares